In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday ...

We recently published a list of Smart Money Ratings For 20 Most Undervalued Stocks. In this article, we are going to take a ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other ...

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm Robbins ...

Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D. retired from his role as Immunovant CEO ...

Immunovant, Inc. announced significant leadership changes and strategic developments, including the appointment of Eric Venker, M.D. as CEO and Tiago Girao as CFO, following the retirement of ...

Immunovant on Monday announced changes to its management team, including the naming of a new chief executive, intended to give its majority owner, Roivant Sciences, greater control over the ...

Immunovant announced a leadership change with Eric Venker, M.D., currently President and COO of Roivant, appointed as CEO, succeeding Dr. Pete Salzmann, who has retired from his position.

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal ...